JP2015502926A5 - - Google Patents

Download PDF

Info

Publication number
JP2015502926A5
JP2015502926A5 JP2014541555A JP2014541555A JP2015502926A5 JP 2015502926 A5 JP2015502926 A5 JP 2015502926A5 JP 2014541555 A JP2014541555 A JP 2014541555A JP 2014541555 A JP2014541555 A JP 2014541555A JP 2015502926 A5 JP2015502926 A5 JP 2015502926A5
Authority
JP
Japan
Prior art keywords
tautomer
stereoisomer
proportions
mixture
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014541555A
Other languages
English (en)
Japanese (ja)
Other versions
JP6096792B2 (ja
JP2015502926A (ja
Filing date
Publication date
Priority claimed from DE102011118830A external-priority patent/DE102011118830A1/de
Application filed filed Critical
Publication of JP2015502926A publication Critical patent/JP2015502926A/ja
Publication of JP2015502926A5 publication Critical patent/JP2015502926A5/ja
Application granted granted Critical
Publication of JP6096792B2 publication Critical patent/JP6096792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014541555A 2011-11-18 2012-10-30 癌治療における使用のためのモルホリニルベンゾトリアジン Active JP6096792B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011118830.8 2011-11-18
DE102011118830A DE102011118830A1 (de) 2011-11-18 2011-11-18 Morpholinylbenzotriazine
PCT/EP2012/004542 WO2013072015A1 (de) 2011-11-18 2012-10-30 Morpholinylbenzotriazine zur anwendung in der krebstherapie

Publications (3)

Publication Number Publication Date
JP2015502926A JP2015502926A (ja) 2015-01-29
JP2015502926A5 true JP2015502926A5 (US20070167479A1-20070719-C00034.png) 2015-12-24
JP6096792B2 JP6096792B2 (ja) 2017-03-15

Family

ID=47143824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014541555A Active JP6096792B2 (ja) 2011-11-18 2012-10-30 癌治療における使用のためのモルホリニルベンゾトリアジン

Country Status (24)

Country Link
US (1) US9187469B2 (US20070167479A1-20070719-C00034.png)
EP (1) EP2780332B1 (US20070167479A1-20070719-C00034.png)
JP (1) JP6096792B2 (US20070167479A1-20070719-C00034.png)
KR (1) KR20140097391A (US20070167479A1-20070719-C00034.png)
CN (1) CN103930408B (US20070167479A1-20070719-C00034.png)
AU (1) AU2012339196B2 (US20070167479A1-20070719-C00034.png)
BR (1) BR112014011805A2 (US20070167479A1-20070719-C00034.png)
CA (1) CA2856103C (US20070167479A1-20070719-C00034.png)
DE (1) DE102011118830A1 (US20070167479A1-20070719-C00034.png)
DK (1) DK2780332T3 (US20070167479A1-20070719-C00034.png)
EA (1) EA201400595A1 (US20070167479A1-20070719-C00034.png)
ES (1) ES2572605T3 (US20070167479A1-20070719-C00034.png)
HK (1) HK1199875A1 (US20070167479A1-20070719-C00034.png)
HR (1) HRP20160495T1 (US20070167479A1-20070719-C00034.png)
HU (1) HUE027577T2 (US20070167479A1-20070719-C00034.png)
IL (1) IL232577A (US20070167479A1-20070719-C00034.png)
IN (1) IN2014KN01287A (US20070167479A1-20070719-C00034.png)
MX (1) MX2014005838A (US20070167479A1-20070719-C00034.png)
PL (1) PL2780332T3 (US20070167479A1-20070719-C00034.png)
RS (1) RS54768B1 (US20070167479A1-20070719-C00034.png)
SG (1) SG11201402206YA (US20070167479A1-20070719-C00034.png)
SI (1) SI2780332T1 (US20070167479A1-20070719-C00034.png)
WO (1) WO2013072015A1 (US20070167479A1-20070719-C00034.png)
ZA (1) ZA201404438B (US20070167479A1-20070719-C00034.png)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2841428T (pt) 2012-04-24 2018-11-29 Vertex Pharma Inibidores de adn-pk
EP3985003B1 (en) 2013-03-12 2023-08-09 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
CN105814036B (zh) 2013-10-17 2018-10-26 沃泰克斯药物股份有限公司 作为dna-pk抑制剂的共晶
KR20190062485A (ko) 2016-09-27 2019-06-05 버텍스 파마슈티칼스 인코포레이티드 Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
CN107793373B (zh) * 2017-10-31 2019-09-17 广西师范大学 2-取代苯并三嗪酮衍生物及其制备方法
EA202091708A1 (ru) * 2018-01-17 2020-11-10 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы днк-пк
WO2021083936A1 (en) 2019-11-01 2021-05-06 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
WO2022268648A1 (en) 2021-06-24 2022-12-29 Syngenta Crop Protection Ag 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides
WO2023247360A1 (en) 2022-06-21 2023-12-28 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9190155U1 (de) 1990-11-06 1993-10-07 Pfizer Inc., New York, N.Y. Chinazolinderivate zur Steigerung der Antitumoraktivität
AU4972900A (en) 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
AU2001288432A1 (en) * 2000-09-01 2002-03-22 Icos Corporation Materials and methods to potentiate cancer treatment
US7291733B2 (en) * 2003-10-10 2007-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted tricyclic heterocycles and their uses
CN101230045B (zh) * 2008-02-14 2013-04-10 沈阳药科大学 芳环并三嗪类衍生物及其应用
SG183855A1 (en) * 2010-03-16 2012-10-30 Merck Patent Gmbh Morpholinylquinazolines

Similar Documents

Publication Publication Date Title
JP2015502926A5 (US20070167479A1-20070719-C00034.png)
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
WO2015095227A3 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
CL2014001792A1 (es) Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades.
MY187047A (en) Selective pyy compounds and uses thereof
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
JP2015500225A5 (US20070167479A1-20070719-C00034.png)
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
HRP20211177T1 (hr) Korteksolon 17alfa-valerat za uporabu u liječenju tumora
EA201591686A1 (ru) Пиридинильные и конденсированные пиридинильные производные триазолона
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
PH12016502353A1 (en) Pharmaceutical composition
PH12016502352A1 (en) Pharmaceutical composition
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
RU2017141536A (ru) Замещенные производные индол-5-ола и их терапевтические применения
TN2015000386A1 (en) Formulations of organic compounds
JP2015507020A5 (US20070167479A1-20070719-C00034.png)
WO2015035410A8 (en) Cancer therapy
JP2014148552A5 (US20070167479A1-20070719-C00034.png)
JP2016515550A5 (US20070167479A1-20070719-C00034.png)
MX2016014699A (es) (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.